Compare with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES ALEMBIC PHARMA ALKEM LABORATORIES/
ALEMBIC PHARMA
 
P/E (TTM) x - 15.6 - View Chart
P/BV x 6.6 3.6 185.2% View Chart
Dividend Yield % 0.7 1.1 61.4%  

Financials

 ALKEM LABORATORIES   ALEMBIC PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ALEMBIC PHARMA
Mar-19
ALKEM LABORATORIES/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589664 239.3%   
Low Rs1,232412 298.7%   
Sales per share (Unadj.) Rs417.5208.7 200.0%  
Earnings per share (Unadj.) Rs56.331.0 181.6%  
Cash flow per share (Unadj.) Rs64.737.1 174.4%  
Dividends per share (Unadj.) Rs12.705.50 230.9%  
Dividend yield (eoy) %0.91.0 88.1%  
Book value per share (Unadj.) Rs292.9144.2 203.1%  
Shares outstanding (eoy) m119.57188.52 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.6 131.0%   
Avg P/E ratio x25.117.4 144.3%  
P/CF ratio (eoy) x21.814.5 150.3%  
Price / Book Value ratio x4.83.7 129.0%  
Dividend payout %22.617.7 127.1%   
Avg Mkt Cap Rs m168,653101,461 166.2%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1717,467 122.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,91539,347 126.9%  
Other income Rs m1,64594 1,753.8%   
Total revenues Rs m51,56139,441 130.7%   
Gross profit Rs m8,4828,736 97.1%  
Depreciation Rs m1,0061,152 87.3%   
Interest Rs m671184 364.3%   
Profit before tax Rs m8,4517,493 112.8%   
Minority Interest Rs m-11411 -1,053.7%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,568 102.5%   
Profit after tax Rs m6,7315,844 115.2%  
Gross profit margin %17.022.2 76.5%  
Effective tax rate %19.020.9 90.8%   
Net profit margin %13.514.9 90.8%  
BALANCE SHEET DATA
Current assets Rs m27,06219,577 138.2%   
Current liabilities Rs m15,32414,896 102.9%   
Net working cap to sales %23.511.9 197.7%  
Current ratio x1.81.3 134.4%  
Inventory Days Days6790 74.1%  
Debtors Days Days4145 91.0%  
Net fixed assets Rs m12,61027,097 46.5%   
Share capital Rs m239377 63.4%   
"Free" reserves Rs m34,49026,811 128.6%   
Net worth Rs m35,02727,188 128.8%   
Long term debt Rs m1,2124,993 24.3%   
Total assets Rs m54,38747,778 113.8%  
Interest coverage x13.641.7 32.6%   
Debt to equity ratio x00.2 18.8%  
Sales to assets ratio x0.90.8 111.4%   
Return on assets %13.612.6 107.9%  
Return on equity %19.221.5 89.4%  
Return on capital %24.923.6 105.3%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56319,453 33.7%   
Fx outflow Rs m3,0126,065 49.7%   
Net fx Rs m3,55213,388 26.5%   
CASH FLOW
From Operations Rs m7,2598,120 89.4%  
From Investments Rs m1,864-7,556 -24.7%  
From Financial Activity Rs m-9,273590 -1,570.6%  
Net Cashflow Rs m-1501,153 -13.0%  

Share Holding

Indian Promoters % 66.9 74.1 90.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 2.9 1,141.4%  
FIIs % 0.0 9.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 13.9 -  
Shareholders   68,381 49,328 138.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  NATCO PHARMA  ELDER PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS